Home › Diastolic Heart Failure › NCT06015776

Purinergic Signaling and the Postmenopausal Heart

PGC-1, Purines and the Postmenopausal Heart

Who can join

Ages 30 to 88 · All sexes

Inclusion Criteria:

* Patients undergoing cardiac surgery under cardiopulmonary bypass.

Exclusion Criteria:

* Refusal to participate
* Emergency surgery
* Pre-existing heart block
* Preexisting atrial fibrillation
* Redo surgery
* Estrogen or hormone replacement therapy
* History of chronic heart failure
* History of major kidney disease

About the study

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

What is being tested

• Gender (other)

Sponsor: Beth Israel Deaconess Medical Center · Participants: 500 · Started: Jul 1, 2019

Contact the study team

• Robina Matyal, MD · Phone: 6176401208

Official record on ClinicalTrials.gov — NCT06015776

Locations in the U.S.

Conditions

• Diastolic Heart Failure

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.